Melemedjian, O. K., Asiedu, M. N., Tillu, D. V., Sanoja, R., Yan, J., Lark, A., . . . Price, T. J. (2011). Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. BioMed Central.
Chicago-stil citatMelemedjian, Ohannes K., et al. Targeting Adenosine Monophosphate-activated Protein Kinase (AMPK) in Preclinical Models Reveals a Potential Mechanism for the Treatment of Neuropathic Pain. BioMed Central, 2011.
MLA-referensMelemedjian, Ohannes K., et al. Targeting Adenosine Monophosphate-activated Protein Kinase (AMPK) in Preclinical Models Reveals a Potential Mechanism for the Treatment of Neuropathic Pain. BioMed Central, 2011.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.